These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33924378)

  • 1. Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation.
    Prat M; Salon M; Allain T; Dubreuil O; Noël G; Preisser L; Jean B; Cassard L; Lemée F; Tabah-Fish I; Pipy B; Jeannin P; Prost JF; Barret JM; Coste A
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33924378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
    Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
    Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer.
    Barret JM; Nicolas A; Jarry A; Dubreuil O; Meseure D; Passat T; Perrial E; Deleine C; Champenois G; Gaillard S; Duchalais E; Ray-Coquard I; Lahmar M; Dumontet C; Bennouna J; Bossard C; Roman-Roman S; Prost JF
    Biology (Basel); 2021 Apr; 10(4):. PubMed ID: 33917111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages.
    Bougherara H; Némati F; Nicolas A; Massonnet G; Pugnière M; Ngô C; Le Frère-Belda MA; Leary A; Alexandre J; Meseure D; Barret JM; Navarro-Teulon I; Pèlegrin A; Roman-Roman S; Prost JF; Donnadieu E; Decaudin D
    Oncotarget; 2017 Nov; 8(59):99950-99965. PubMed ID: 29245952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
    Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.
    Song JY; Chen KY; Kim SY; Kim MR; Ryu KS; Cha JH; Kang CS; MacLaughlin DT; Kim JH
    Int J Oncol; 2009 Jun; 34(6):1583-91. PubMed ID: 19424576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
    Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
    Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts.
    Goletz C; Lischke T; Harnack U; Schiele P; Danielczyk A; Rühmann J; Goletz S
    Front Immunol; 2018; 9():1614. PubMed ID: 30061887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA expression in the healthy and cancerous endometria.
    Kim SM; Kim YO; Lee MK; Chung YJ; Jeung IC; Kim MR; Kim JH
    Oncol Lett; 2019 Jan; 17(1):532-538. PubMed ID: 30655798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
    Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
    Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
    Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity.
    Natoli M; Herzig P; Pishali Bejestani E; Buchi M; Ritschard R; Lloyd GK; Mohanlal R; Tonra JR; Huang L; Heinzelmann V; Trüb M; Zippelius A; Kashyap AS
    Front Oncol; 2021; 11():644608. PubMed ID: 33747968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression during postnatal testis development and in the adult testis of the rat.
    Baarends WM; Hoogerbrugge JW; Post M; Visser JA; De Rooij DG; Parvinen M; Themmen AP; Grootegoed JA
    Endocrinology; 1995 Dec; 136(12):5614-22. PubMed ID: 7588316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
    Campbell KS; Cohen AD; Pazina T
    Front Immunol; 2018; 9():2551. PubMed ID: 30455698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth.
    Baarends WM; Uilenbroek JT; Kramer P; Hoogerbrugge JW; van Leeuwen EC; Themmen AP; Grootegoed JA
    Endocrinology; 1995 Nov; 136(11):4951-62. PubMed ID: 7588229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Müllerian-Inhibiting Substance/Anti-Müllerian Hormone Type II Receptor in the Human Theca Cells.
    Cheon KY; Chung YJ; Cho HH; Kim MR; Cha JH; Kang CS; Lee JY; Kim JH
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3376-3385. PubMed ID: 29947765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognate Interaction With CD4
    Eisel D; Das K; Dickes E; König R; Osen W; Eichmüller SB
    Front Immunol; 2019; 10():219. PubMed ID: 30853959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
    Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
    MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.